International Journal of Nanomedicine · 2009 · 41 citations · 23 references
MedicineOncologyPharmacologyApoptosisCancer PharmacologyChemotherapyApoptosis In CancerApoptosis ModulationApoptosis PharmacologyApoptosis ResistanceMultidrug ResistanceAntiapoptotic BalanceAntiapoptotic Protein RegulationAnticancer ActivityAnticancer ChemotherapyAnticancer Drug ResistanceCombination TherapyIron Oxide NanoparticlesMultidrug Resistance Mechanisms
Apoptosis is a common pathway that finally mediated the killing functions of anticancer drugs, which is an important cause of multidrug resistance (MDR). The aim of this study was to investigate the potential benefit of combination therapy with magnetic nanoparticle of Fe(3)O(4) (MNP(Fe(3)O(4))) and 5-bromotetrandrin (BrTet). Analysis of the apoptosis percentage showed that combination of daunorubicin (DNR) with either MNP(Fe(3)O(4)) or BrTet exerted a potent cytotoxic effect on K562/A02 cells, while MNP(Fe(3)O(4)) and BrTet cotreatment can synergistically enhance DNR-induced apoptosis. Importantly, we confirmed that the distinct synergism effect of that composite on reverse multidrug resistance may owe to the regulation of various proliferative and antiapoptotic gene products, including P53 and caspase-3. Thus our in vitro data strongly suggests a potential clinical application of MNP(Fe(3)O(4)) and BrTet combination on CML.
23
Magnetic nanoparticles for drug delivery
Manuel Arruebo, Rodrigo Fernández‐Pacheco, M. R. Ibarra et al. · Nano Today · 2007 · 1.6K citations
Magnetic nanoparticles for drug delivery
Jon Dobson · Drug Development Research · 2006 · 881 citations · Full text
Apoptosis and the Dilemma of Cancer Chemotherapy
Yusuf A. Hannun · Blood · 1997 · 638 citations · Full text
Medicine, Cancer Biology, Oncology +12
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy
Kensuke Kojima, Marina Konopleva, Ismael Samudio et al. · Blood · 2005 · 406 citations · Full text